Interventions for the treatment of uveitic macular edema: a systematic review and meta-analysis
- PMID: 23807831
- PMCID: PMC3685443
- DOI: 10.2147/OPTH.S40268
Interventions for the treatment of uveitic macular edema: a systematic review and meta-analysis
Abstract
Background: Uveitic macular edema is the major cause of reduced vision in eyes with uveitis.
Objectives: To assess the effectiveness of interventions in the treatment of uveitic macular edema.
Search strategy: Cochrane Central Register of Controlled Trials, Medline, and Embase. There were no language or data restrictions in the search for trials. The databases were last searched on December 1, 2011. Reference lists of included trials were searched. Archives of Ophthalmology, Ophthalmology, Retina, the British Journal of Ophthalmology, and the New England Journal of Medicine were searched for clinical trials and reviews.
Selection criteria: Participants of any age and sex with any type of uveitic macular edema were included. Early, chronic, refractory, or secondary uveitic macular edema were included. We included trials that compared any interventions of any dose and duration, including comparison with another treatment, sham treatment, or no treatment.
Data collection and analysis: Best-corrected visual acuity and central macular thickness were the primary outcome measures. Secondary outcome data including adverse effects were collected.
Conclusion: More results from randomized controlled trials with long follow-up periods are needed for interventions for uveitic macular edema to assist in determining the overall long-term benefit of different treatments. The only intervention with sufficiently robust randomized controlled trials for a meta-analysis was acetazolamide, which was shown to be ineffective in improving vision in eyes with uveitic macular edema, and is clinically now rarely used. Interventions showing promise in this disease include dexamethasone implants, immunomodulatory drugs and anti-vascular endothelial growth-factor agents. When macular edema has become refractory after multiple interventions, pars plana vitrectomy could be considered. The disease pathophysiology is uncertain and the course of disease unpredictable. As there are no clear guidelines from the literature, interventions should be tailored to the individual patient.
Keywords: uveitic macular edema; uveitis.
Figures
Similar articles
-
Dexamethasone intravitreal implant for treatment of uveitic persistent cystoid macular edema in vitrectomized patients.Retina. 2013 Jul-Aug;33(7):1435-40. doi: 10.1097/IAE.0b013e31827e247b. Retina. 2013. PMID: 23514796
-
Intravitreal bevacizumab in refractory uveitic macular edema: one-year follow-up.Eur J Ophthalmol. 2009 Jul-Aug;19(4):622-9. doi: 10.1177/112067210901900417. Eur J Ophthalmol. 2009. PMID: 19551679
-
The future of Cochrane Neonatal.Early Hum Dev. 2020 Nov;150:105191. doi: 10.1016/j.earlhumdev.2020.105191. Epub 2020 Sep 12. Early Hum Dev. 2020. PMID: 33036834
-
The effectiveness of pharmacological agents for the treatment of uveitic macular oedema (UMO): a systematic review protocol.Syst Rev. 2016 Feb 13;5:29. doi: 10.1186/s13643-016-0203-y. Syst Rev. 2016. PMID: 26872918 Free PMC article.
-
Medical treatment of cystoid macular edema.Ocul Immunol Inflamm. 2002 Dec;10(4):239-46. doi: 10.1076/ocii.10.4.239.15589. Ocul Immunol Inflamm. 2002. PMID: 12854032 Review.
Cited by
-
Immunity status and expression of molecular markers (ICAM-1, CD5, CD25, CD95) on lymphocytes of patients with recurrent anterior uveitis complicated by macular edema.Graefes Arch Clin Exp Ophthalmol. 2023 May;261(5):1423-1431. doi: 10.1007/s00417-022-05938-6. Epub 2022 Dec 24. Graefes Arch Clin Exp Ophthalmol. 2023. PMID: 36565328
-
Photodynamic Therapy for Chorioretinal Diseases: A Practical Approach.Ophthalmol Ther. 2020 Jun;9(2):329-342. doi: 10.1007/s40123-020-00250-0. Epub 2020 Apr 11. Ophthalmol Ther. 2020. PMID: 32279234 Free PMC article.
-
Risk factors for the development of macular edema in children with uveitis.Front Ophthalmol (Lausanne). 2023 Jun 2;3:1134077. doi: 10.3389/fopht.2023.1134077. eCollection 2023. Front Ophthalmol (Lausanne). 2023. PMID: 38983006 Free PMC article.
-
Safety and Efficacy of Suprachoroidal Injection of Triamcinolone in Treating Macular Edema Secondary to Noninfectious Uveitis.Cureus. 2021 Nov 30;13(11):e20038. doi: 10.7759/cureus.20038. eCollection 2021 Nov. Cureus. 2021. PMID: 34993024 Free PMC article.
-
Results of intravitreal dexamethasone implant 0.7 mg (Ozurdex®) in non-infectious posterior uveitis.Int J Ophthalmol. 2015 Aug 18;8(4):835-8. doi: 10.3980/j.issn.2222-3959.2015.04.34. eCollection 2015. Int J Ophthalmol. 2015. PMID: 26309888 Free PMC article.
References
-
- Okhravi N, Lightman S. Cystoid macular edema in uveitis. Ocul Immunol Inflamm. 2003;11:29–38. - PubMed
-
- Ossewaarde-van Norel A, Rothova A. Clinical review: Update on treatment of inflammatory macular edema. Ocul Immunol Inflamm. 2011;19:75–83. - PubMed
-
- de Smet M, Taylor S, Bodaghi B, et al. Understanding uveitis: the impact of research on visual outcomes. Prog Retin Eye Res. 2011;30:452–470. - PubMed
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials
Miscellaneous